Seegene submits COVID-19, flu assay for FDA EUA

March 5, 2021

Seegene has submitted its Allplex SARS-CoV-2/FluA/FluB/RSV Assay to the U.S. Food and Drug Administration for emergency use authorization (EUA), according to a company news release.

Seegene's Allplex SARS-CoV-2/FluA/FluB/RSV Assay is a real-time RT-PCR assay that can simultaneously detect and differentiate 8 target genes including Flu A, Flu B, RSV A/B and three different target genes of COVID-19 (S gene, RdRP gene and N gene). The assay also includes dual targets for internal control (endogenous and exogenous respectively) in the same reaction tube.

The Allplex SARS-CoV-2/FluA/FluB/RSV Assay is currently available in Europe and elsewhere around the world.

Visit Seegene for more news